



Standing Way Eaglestone Milton Keynes MK6 5LD 01908 660033 www.mkuh.nhs.uk

## Request under Freedom of Information Act 2000

Thank you for your request for information which we received on 12 October 2018.

I am pleased to confirm the following.

## 1. Within your trust how many patients do you have diagnosed with Rheumatoid Arthritis?

564

2. How many Rheumatoid Arthritis patients have had an IFR [Individual Funding Request] put in for them to have an advanced treatment (i.e. biologic or JAK inhibitor) in the past 12 months?

46 <u>Rheumatology</u> patients have received a new biologics or JAK inhibitor in the last 12 months and will therefore have had an IFR completed. The Trust cannot specifically identify whether the patient had Rheumatoid Arthritis or any other diagnosis.

3. How many patients do you have diagnosed with <u>moderate</u> Rheumatoid Arthritis? [moderate is defined within the guidelines as patients with a DAS score of between 3.2 and 5.1]

The Trust does not record this information in a central location. To obtain this information would entail trawling through patient records which would require permission and exceed the appropriate time limit.

4. How many <u>moderate</u> Rheumatoid Arthritis patients have had an IFR [Individual Funding Request] put in for them to have an advanced treatment (i.e. biologic or JAK inhibitor) in the past 12 months?

46

5. How many <u>moderate</u> Rheumatoid Arthritis patients have been granted an IFR request for an advanced treatment (i.e. biologic or JAK inhibitor) in the past 12 months?

46

6. If possible, please state the number of patients and the name of an advanced treatment (i.e. biologic or JAK inhibitor) provided

Adalimumab	15
Baritinib	1
Certolizumab	1
Etanercept	15
Rituximab	9
Secukinumab	2

As a teaching hospital, we conduct education and research to improve healthcare for our patients. During your visit students may be involved in your care, or you may be asked to participate in a clinical trial. Please speak to your doctor or nurse if you have any concerns.

Tocilizumab	1
Ustekinumab	2

You are advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD. If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely,

Freedom Of Information Co-ordinator For and on behalf of Milton Keynes Hospital NHS Foundation Trust

> Any re-use of this information will be subject to the 'Re-use of Public Sector Information Regulations' and best practice.